Epithelial to Mesenchymal Transition in Patients with Pancreatic Ductal Adenocarcinoma: State-of-the-Art and Therapeutic Opportunities
Pancreatic ductal adenocarcinoma (PDAC) is one of the malignancies with the worst prognosis despite a decade of efforts. Up to eighty percent of patients are managed at late stages with metastatic disease, in part due to a lack of diagnosis. The effectiveness of PDAC therapies is challenged by the e...
Main Authors: | Julie Dardare, Andréa Witz, Jean-Louis Merlin, Agathe Bochnakian, Paul Toussaint, Pauline Gilson, Alexandre Harlé |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/8/740 |
Similar Items
-
DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy
by: Julie Dardare, et al.
Published: (2022-12-01) -
Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma
by: Ann Mary Joseph, et al.
Published: (2024-02-01) -
An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma
by: Zengyu Feng, et al.
Published: (2021-04-01) -
Metabolism remodeling in pancreatic ductal adenocarcinoma
by: Jin-Tao Li, et al.
Published: (2019-11-01) -
Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC)
by: Han Yin, et al.
Published: (2024-08-01)